reverse transcriptase inhibitors Archives

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Hanh Thi Pham PhD, Meng A Xiao BSc, Miguel AV Principe BSc, Alexander Wong MD, Thibault Mesplède PhD

Article Type

Review

Published

03 Mar 2020

This review summarizes chemical, pharmacological, and clinical information about doravirine with an emphasis on drug resistance. The efficacy results from an early phase clinical trial evaluating doravirine in combination with islatravir are also provided.